Point-of-care diagnostics approaches for detection of lung cancer-associated circulating miRNAs

Drug Discov Today. 2021 Jun;26(6):1501-1509. doi: 10.1016/j.drudis.2021.02.023. Epub 2021 Feb 26.

Abstract

Circulating cell-free miRNAs (ccf-miRs) have gained significant interest as biomarkers for lung cancer (LC) diagnosis. However, the clinical application of ccf-miRs is mainly limited by time, cost, and expertise-related problems of existing detection strategies. Recently, the development of different point-of-care (POC) approaches offers useful on-site platforms, because these technologies have important features such as portability, rapid turnaround time, minimal sample requirement, and cost-effectiveness. In this review, we discuss different POC approaches for detecting ccf-miRs and highlight the utility of incorporating nanomaterials for enhanced biorecognition and signal transduction, further improving their diagnostic applicability in LC settings.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor / genetics
  • Cell-Free Nucleic Acids / genetics
  • Circulating MicroRNA / genetics*
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / genetics
  • Nanostructures
  • Point-of-Care Testing*

Substances

  • Biomarkers, Tumor
  • Cell-Free Nucleic Acids
  • Circulating MicroRNA